Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenvacibart for Secondary Stroke Prevention (ROXI-DAISEN)
NCT07876492Phase 3Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2026
- Primary completion
- Dec 2029
01
Overview
A Phase 3 trial of cenvacibart in ischemic stroke, Transient Ischemic Attack (TIA), sponsored by Regeneron Pharmaceuticals. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
cenvacibart
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT07876492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07876492.